Leerink Swann Weighs in on Nevro Corp’s FY2017 Earnings (NVRO)

Nevro Corp (NYSE:NVRO) – Analysts at Leerink Swann dropped their FY2017 EPS estimates for Nevro in a report issued on Sunday. Leerink Swann analyst D. Antalffy now forecasts that the medical equipment provider will post earnings per share of ($1.20) for the year, down from their prior estimate of ($1.19). Leerink Swann currently has a “Outperform” rating and a $110.00 target price on the stock. Leerink Swann also issued estimates for Nevro’s Q1 2018 earnings at ($0.13) EPS, Q2 2018 earnings at ($0.06) EPS, Q3 2018 earnings at ($0.03) EPS, FY2018 earnings at ($0.20) EPS, Q4 2019 earnings at $0.14 EPS and FY2020 earnings at $0.81 EPS.

Nevro (NYSE:NVRO) last released its quarterly earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. Nevro had a negative return on equity of 17.27% and a negative net margin of 14.09%. The firm had revenue of $82.26 million for the quarter, compared to analyst estimates of $80.50 million. During the same quarter in the previous year, the company posted ($0.14) EPS. The business’s revenue was up 35.0% on a year-over-year basis.

Other equities research analysts have also issued research reports about the company. BidaskClub lowered Nevro from a “hold” rating to a “sell” rating in a research report on Saturday, October 28th. TheStreet upgraded Nevro from a “d+” rating to a “c-” rating in a research report on Monday, November 6th. ValuEngine lowered Nevro from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. BMO Capital Markets reiterated a “buy” rating and issued a $100.00 price target on shares of Nevro in a research report on Thursday, December 14th. Finally, Northland Securities reiterated a “buy” rating and issued a $96.00 price target on shares of Nevro in a research report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Nevro has an average rating of “Hold” and an average target price of $99.25.

Shares of Nevro (NYSE:NVRO) opened at $77.07 on Wednesday. Nevro has a 52-week low of $65.00 and a 52-week high of $99.63. The company has a market capitalization of $2,222.12, a PE ratio of -53.15 and a beta of -0.59. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.78 and a quick ratio of 6.81.

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Nevro by 2.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,973,146 shares of the medical equipment provider’s stock valued at $146,862,000 after purchasing an additional 38,553 shares in the last quarter. BlackRock Inc. boosted its position in shares of Nevro by 13.5% during the 2nd quarter. BlackRock Inc. now owns 1,787,896 shares of the medical equipment provider’s stock valued at $133,073,000 after purchasing an additional 212,656 shares in the last quarter. Janus Henderson Group PLC acquired a new position in Nevro during the 2nd quarter worth approximately $105,837,000. Jennison Associates LLC raised its stake in Nevro by 12.6% during the 4th quarter. Jennison Associates LLC now owns 1,282,874 shares of the medical equipment provider’s stock worth $88,570,000 after buying an additional 143,962 shares during the period. Finally, Wells Fargo & Company MN raised its stake in Nevro by 11.1% during the 3rd quarter. Wells Fargo & Company MN now owns 1,082,072 shares of the medical equipment provider’s stock worth $98,338,000 after buying an additional 108,289 shares during the period.

In related news, CFO Andrew H. Galligan sold 7,000 shares of the company’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $75.11, for a total transaction of $525,770.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 9.10% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/07/leerink-swann-weighs-in-on-nevro-corps-fy2017-earnings-nvro.html.

Nevro Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply